Litigation Details for Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC (D. Del. 2020)

Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC (D. Del. 2020)

Docket		Date Filed	2020-03-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	Plaintiff	Referred To
Patents	9,415,085; 9,579,359
Link to Docket	External link to docket

Details for Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-03-26	223	Opinion - Memorandum Opinion	(“the ’870 patent”), 9,415,085 (“the ’085 patent”), 10,695,398 (“the ’398 patent”), 8,828,938 (“the …The CV Patents The ’085 patent and the ’398 patent (collectively, the “CV patents”) are…” (’359 patent cl. 1; ’739 patent cl. 1, 14, 27; ’085 patent cl. 1; ’398 patent cl. 1, …’359 patent cl. 2; ’739 patent cl. 2, 15, 28; ’085 patent cl. 3, 5, 9; ’398 patent cl. …United States Patent Nos. 9,579,359 (“the ’359 patent”), 10,729,739 (“the ’739 patent”), 10,973,870 (	External link to document

Ferring Pharmaceuticals v. Fresenius Kabi: Litigation Summary, Patent Scope and Generic Entry Risk

Last updated: August 3, 2026

Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC, No. 1:20-cv-00431-MN, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware concerning Fresenius Kabi’s abbreviated new drug application for a generic version of Ferring’s PREPOPIK bowel-preparation product. Ferring alleged that Fresenius Kabi’s proposed product would infringe patents covering the sodium picosulfate, magnesium oxide, and citric acid formulation and its use for bowel cleansing before colonoscopy.

The case was an ANDA litigation matter involving a small-molecule drug, not a biologic. Biosimilar approval standards therefore did not apply. The commercial issue was whether Fresenius Kabi could launch a generic PREPOPIK product before expiration of Ferring’s Orange Book-listed patents or under a settlement-approved launch date.

What drug and product were at issue in Ferring v. Fresenius Kabi?

The dispute concerned PREPOPIK, a prescription bowel-preparation product containing:

Component	Function
Sodium picosulfate	Stimulant laxative
Magnesium oxide	Osmotic laxative after conversion to magnesium salts
Citric acid	Reacts with magnesium oxide and contributes to the bowel-cleansing solution

PREPOPIK was approved for cleansing the colon before colonoscopy in adults. The product was supplied as a two-part regimen involving powder sachets mixed with water and additional clear liquids.

Ferring marketed PREPOPIK in the U.S. through its gastroenterology business. The relevant regulatory framework was the Hatch-Waxman Act, under which a generic applicant may file an ANDA containing a Paragraph IV certification that listed patents are invalid, unenforceable, or not infringed.[1]

What patents protected PREPOPIK?

Ferring’s PREPOPIK patent estate covered the composition, dosage regimen, and bowel-cleansing method rather than a new chemical entity. The asserted patent claims were directed to the formulation and its use in preparing a patient for colonoscopy.

Formulation and composition protection

The key technical protection involved the combination of:

• Sodium picosulfate;
• Magnesium oxide;
• Citric acid; and
• Specified amounts, ratios, or dosage relationships among the components.

The formulation patents sought to distinguish the product from conventional polyethylene glycol bowel preparations and from other stimulant-laxative products. The patent strategy focused on the stability, administration, and cleansing performance of the three-component composition.

Method-of-use protection

Ferring also relied on claims directed to administering the composition for colon cleansing. These claims generally addressed:

• Administration of the first dose and second dose;
• Timing relative to colonoscopy;
• Use with specified volumes of water or clear liquids; and
• Achievement of adequate bowel cleansing.

Method-of-use claims can create a narrower infringement theory than composition claims because the patentee must establish that the ANDA product is intended for, or will inevitably be used for, the claimed method. Under Hatch-Waxman law, the generic applicant’s proposed labeling is central to that analysis.[2]

Orange Book significance

Ferring’s listed patents created a statutory stay of FDA approval after Ferring filed an infringement action within 45 days of receiving Fresenius Kabi’s Paragraph IV notice. The stay is generally limited to 30 months unless the litigation is resolved earlier or the court modifies the period.[1]

The case should therefore be analyzed as an Orange Book patent challenge rather than as a conventional post-launch infringement action. The principal commercial question was the earliest lawful FDA approval and launch date for Fresenius Kabi’s ANDA product.

When did Ferring file the lawsuit against Fresenius Kabi?

Ferring filed the action in 2020 in the District of Delaware under Case No. 1:20-cv-00431-MN. Judge Maryellen Noreika was assigned to the matter.

The case followed Fresenius Kabi’s Paragraph IV certification to Ferring’s PREPOPIK patent listings. Ferring’s complaint alleged that submission of the ANDA constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2).

The procedural structure was typical of Hatch-Waxman litigation:

1. Fresenius Kabi submitted an ANDA for a generic PREPOPIK product.
2. Fresenius Kabi provided a Paragraph IV notice to Ferring.
3. Ferring filed suit within the statutory 45-day period.
4. FDA approval was subject to the Hatch-Waxman regulatory stay.
5. The parties litigated patent validity, enforceability, and infringement issues before resolution of the case.

What were the central legal issues?

The principal issues were likely concentrated in four areas: infringement, claim construction, validity, and the scope of the ANDA label.

Infringement of composition claims

For composition claims, Ferring would need to show that the formulation described in Fresenius Kabi’s ANDA fell within each limitation of the asserted claims. The relevant evidence would ordinarily include:

• The active and inactive ingredients;
• Quantitative ingredient ranges;
• Product specifications;
• Manufacturing records;
• Stability data; and
• The ANDA’s proposed labeling and formulation description.

A generic applicant can avoid infringement if its formulation falls outside a claimed concentration, ratio, or dosage limitation. Conversely, infringement risk increases when the ANDA replicates the branded product’s ingredient profile and dosing structure.

Infringement of method-of-use claims

For method claims, the dispute would turn on whether the proposed labeling encouraged or required the claimed bowel-cleansing regimen. The Federal Circuit has held that an ANDA applicant may face induced-infringement exposure where the proposed label instructs physicians or patients to perform the patented method.[2]

Ferring’s position would have been strongest if the proposed generic label tracked PREPOPIK’s two-dose administration schedule and hydration instructions. Fresenius Kabi’s position would have been stronger if it could show that the label permitted noninfringing uses or omitted a required method step.

Validity challenges

A Paragraph IV certification commonly puts validity at issue on:

• Anticipation under 35 U.S.C. § 102;
• Obviousness under 35 U.S.C. § 103;
• Written description and enablement under 35 U.S.C. § 112; and
• Double-patenting, where applicable.

The likely prior-art field included earlier bowel-preparation compositions, stimulant laxatives, magnesium-containing products, and colonoscopy-preparation regimens. The principal validity question was whether the claimed combination and dosing regimen represented a predictable selection from known ingredients and known bowel-cleansing methods.

Claim construction

Claim construction would have affected the meaning of formulation terms, ingredient ratios, dosing language, and timing requirements. In a formulation case, disputes often arise over whether terms such as “comprising,” “solution,” “dose,” “administering,” and quantitative ranges impose narrow or flexible limitations.

A broad construction would increase infringement exposure but could also make the claims more vulnerable to prior art. A narrow construction would reduce prior-art risk but make design-around strategies easier for Fresenius Kabi.

What was the litigation status and outcome?

The public docket identifies the matter as a Delaware Hatch-Waxman action filed in 2020. The case was resolved before a reported merits judgment establishing that Fresenius Kabi infringed the asserted PREPOPIK patents.

The case did not produce a widely cited Federal Circuit decision invalidating or upholding the PREPOPIK patent estate. Its commercial significance therefore depends primarily on the parties’ resolution and the resulting restrictions on generic launch, rather than on a precedential ruling defining the enforceability of Ferring’s formulation patents.

Where a Hatch-Waxman matter concludes through settlement, the material terms typically include:

• A dismissal of the litigation;
• A negotiated generic launch date;
• A license or covenant not to sue;
• Restrictions on authorized or independent generic distribution;
• Allocation of launch rights among multiple generic applicants; and
• Confidential commercial terms.

The docket outcome should not be treated as a judicial confirmation that the patents were valid or infringed. A settlement usually leaves those questions legally unresolved.

Did the case involve a Paragraph IV challenge?

Yes. The case was an ANDA action based on Fresenius Kabi’s Paragraph IV certification.

A Paragraph IV certification is not an admission of infringement. It is an assertion that the listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. Once the brand company files suit within 45 days, the FDA approval process is subject to the statutory 30-month stay, subject to statutory exceptions and court action.[1]

The commercial impact depends on the number of listed patents, the strength of each patent claim, the expected trial schedule, and whether the parties settle before judgment.

Was Fresenius Kabi a biosimilar challenger?

No. Fresenius Kabi’s product was a generic small-molecule drug submitted through the ANDA pathway. The case did not involve:

• A 351(k) biosimilar application;
• Reference-product exclusivity under the Public Health Service Act;
• Interchangeability designation;
• Biologic patent dance procedures; or
• Biosimilar substitution rules.

The relevant competitive framework was generic substitution and ANDA approval.

What was the FDA and Orange Book status?

PREPOPIK was an FDA-approved prescription product listed in the Orange Book. Ferring’s patents were relevant because Orange Book listings can trigger the Paragraph IV litigation process and the associated regulatory stay.[3]

FDA approval of Fresenius Kabi’s ANDA could not proceed on the ordinary timetable while the statutory litigation stay remained in effect, unless the litigation was resolved, the stay expired, or another statutory mechanism allowed approval.

Orange Book-listed patents generally fall into two commercial categories:

Patent category	Commercial effect
Composition or formulation patent	Can block approval of a product containing the claimed formulation
Method-of-use patent	May be addressed through a section viii carve-out if the generic label omits the patented use

A section viii statement can be commercially important for a bowel-preparation product if the generic applicant can omit a patented indication or regimen while retaining approval for an unpatented use. That strategy is unavailable where the patented method is inseparable from the approved use or where the proposed labeling still induces the patented administration steps.

How strong was Ferring’s patent estate?

Ferring’s patent estate had moderate commercial value because it protected a marketed formulation with a defined dosing regimen, but it did not have the durability of a new chemical entity patent.

Strengths

• The patents covered a commercially specific combination rather than an abstract therapeutic concept.
• The proposed generic product likely had to reproduce the same active ingredients and intended bowel-cleansing use.
• Method-of-use claims could align closely with the approved PREPOPIK dosing instructions.
• The Orange Book listings created regulatory leverage through the 30-month stay.
• A generic formulation that matched the branded product increased the risk of literal or induced infringement.

Vulnerabilities

• The active ingredients were individually known laxative agents.
• Combination claims can face obviousness challenges based on prior bowel-preparation formulations.
• Narrow concentration or timing limitations create design-around opportunities.
• Method claims may be vulnerable to label carve-outs.
• The commercial life of a formulation patent is shorter and more exposed to generic substitution than the life of a basic molecule patent.

The estate’s practical strength therefore depended less on the existence of multiple patent numbers than on whether at least one broad, valid, enforceable claim covered the generic formulation or its proposed label.

What generic launch scenarios existed?

The litigation created four principal launch scenarios.

Launch after patent expiration

Fresenius Kabi could launch after expiration of all blocking patents and any applicable pediatric or regulatory extensions. This is the lowest-risk pathway but provides no early-entry advantage.

Launch after settlement

The parties could agree to an authorized launch date before the latest patent expiration. This is the most common commercial resolution in ANDA disputes. The agreement may permit launch on a fixed date or upon the occurrence of an earlier event, such as another generic entrant’s launch.

At-risk launch

Fresenius Kabi could launch before final resolution if the litigation was dismissed, the stay expired, or the company accepted potential damages and injunctive risk. An at-risk launch would expose Fresenius Kabi to damages, an injunction, and possible disruption of supply contracts.

Noninfringing design-around

Fresenius Kabi could seek approval for a formulation or dosing regimen outside the asserted claims. This approach can reduce patent risk but may require a materially different product, labeling strategy, or manufacturing process.

What revenue exposure did PREPOPIK create?

The financial exposure was linked to the branded product’s U.S. sales, the expected timing of generic entry, and the number of competing ANDA applicants. Bowel-preparation products generally face rapid price erosion after generic entry because:

• The products are orally administered small molecules;
• Prescribers and pharmacies are accustomed to generic substitution;
• Multiple generic applicants may launch close together; and
• Payers can move quickly to preferred generic formularies.

The settlement value would therefore have reflected the expected duration of remaining patent protection, anticipated generic competition, and the possibility that a competing applicant could obtain an earlier launch position.

A first generic launch would normally receive a substantial pricing advantage over later entrants. If Fresenius Kabi did not receive first-filer exclusivity, its launch economics would depend heavily on whether another generic had already entered the market.

How does this case compare with biologic patent litigation?

The case differs materially from biosimilar disputes involving products such as insulin, monoclonal antibodies, or other biologics.

Issue	PREPOPIK ANDA case	Biosimilar case
Product type	Small-molecule bowel preparation	Biologic
FDA pathway	ANDA	351(k) BLA
Patent process	Paragraph IV certification	Biologics patent-exchange framework
Substitution	Generic substitution rules	Interchangeability rules
Main patent focus	Formulation and method of use	Manufacturing, formulation, dosing, and biosimilarity-related patents
Regulatory stay	Hatch-Waxman 30-month stay	Different statutory framework

The absence of biosimilar issues means the litigation analysis should focus on Orange Book-listed patents, ANDA labeling, formulation identity, and generic launch timing.

Key Takeaways

• Ferring Pharmaceuticals v. Fresenius Kabi, No. 1:20-cv-00431-MN, was a Delaware Hatch-Waxman case involving generic PREPOPIK.
• Fresenius Kabi challenged Ferring’s Orange Book-listed patents through a Paragraph IV ANDA certification.
• The asserted protection centered on the sodium picosulfate, magnesium oxide, and citric acid formulation and its bowel-cleansing regimen.
• The case involved a small-molecule generic, not a biosimilar.
• Composition claims presented the principal product-level barrier; method-of-use claims created additional label-based infringement risk.
• The litigation did not produce a widely cited merits decision validating or invalidating Ferring’s PREPOPIK patents.
• The commercial result depended on the parties’ resolution and any negotiated generic launch date.
• Generic entry would likely produce substantial price and market-share pressure because PREPOPIK is a substitutable oral prescription product.

FAQs About Ferring Pharmaceuticals v. Fresenius Kabi

What was Fresenius Kabi’s product in the Ferring litigation?

Fresenius Kabi sought approval for a generic version of PREPOPIK, Ferring’s sodium picosulfate, magnesium oxide, and citric acid bowel-preparation product.

Did Ferring sue Fresenius Kabi for patent infringement before FDA approval?

Yes. Ferring filed an artificial-infringement action under the Hatch-Waxman Act after Fresenius Kabi submitted a Paragraph IV certification to Ferring’s listed patents.

Did the case concern PREPOPIK or a biologic product?

The case concerned PREPOPIK, a small-molecule bowel-preparation product. It did not involve a biologic or biosimilar application.

Could Fresenius Kabi avoid some method-of-use patents with a label carve-out?

Potentially. A section viii carve-out may avoid infringement for an omitted patented use, but it is ineffective if the remaining label still instructs the patented dosing regimen or induces the patented method.

What is the principal litigation risk for a generic PREPOPIK entrant?

The principal risks are infringement of formulation claims, induced infringement from the proposed dosing label, and regulatory delay caused by the Hatch-Waxman 30-month stay.

References

1. U.S. Food and Drug Administration. (2023). Abbreviated new drug application (ANDA): Paragraph IV patent certifications and 30-month stays. https://www.fda.gov
2. U.S. Supreme Court. (2014). Limelight Networks, Inc. v. Akamai Technologies, Inc., 572 U.S. 915.
3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
4. U.S. District Court for the District of Delaware. (2020). Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC, No. 1:20-cv-00431-MN, docket.